Akebia Therapeutics (AKBA) Stock Gains 17%: What’s Next?


Akebia Therapeutics (AKBA) stock is up more than 17% Tuesday and is higher by 23.3% this week. AKBA stock has fallen -34.6% over the last 12 months, and the average rating from Wall Street analysts is a Moderate Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives AKBA stock a score of 52 out of a possible 100.

That score is mainly influenced by a fundamental score of 73. In addition to the average rating from Wall Street analysts, AKBA stock has a mean target price of $15.00. This means analysts expect the stock to gain 198.80% over the next 12 months. AKBA’s score also includes a short-term technical score of 42. The long-term technical score for AKBA is 42.

Click Here to get the full Stock Score Report on Akebia Therapeutics Inc (AKBA).

What’s Happening with AKBA Stock Today

Akebia Therapeutics Inc (AKBA) stock has gained 17.39% while the S&P 500 has fallen -0.43% as of 2:26 PM on Tuesday, Sep 10. AKBA is up $0.74 from the previous closing price of $4.28 on volume of 1,021,741 shares. Over the past year the S&P 500 is up 3.07% while AKBA has fallen -34.55%. AKBA lost -$2.43 per share in the over the last 12 months.

Symbols: AKBA

You May Also Like